Search

everythinglearnresearchcommunity

for

Search:↓

The user "mallanboy" shared their experience with using 0.5mg Dutasteride once a week, 0.5mg Finasteride every day, and 2.5mg Minoxidil every day for hair loss. They mentioned that their hairline has slightly improved and their hair density has increased after switching from topical minoxidil to oral minoxidil after 8 months. They hope to maintain their results until they are 30 years old for a hair transplant.

User "manlycoffee" shares 25-month progress using Dutasteride, RU58841, Minoxidil, Microneedling, Nizoral, T/GEL, and fixing vitamin D levels for hair loss. Users discuss sources, experiences, and side effects of treatments.

Finasteride made the original poster feel better, with increased energy and less frequent urination, but they were advised to see a doctor due to potential prostate issues. Some users reported positive effects like increased libido and reduced anxiety, while others experienced negative side effects like brain fog and erectile dysfunction.

A user's success story of improving their hair loss with treatments that include finasteride, dutasteride, minoxidil, nizoral, and dermastamping; other products that have been tried with varying results; and potential side effects.

A 25-year-old shared their hair regrowth journey using topical minoxidil, then switching to oral minoxidil and finasteride, experiencing significant improvement but planning a future hair transplant. Other users discussed their experiences with treatments like dutasteride, with some expressing concerns about side effects and treatment effectiveness.

A user shared a 4-month update on their hair regrowth progress using finasteride, minoxidil, a dermaroller, ketoconazole shampoo, multivitamins, and biotin, and received positive reactions and inquiries from others. They also mentioned lifestyle changes such as quitting creatine, alcohol, and smoking, which may have contributed to their success.

The user discussed their positive experience with hair loss treatments Finasteride, Minoxidil, and Dermarolling, showing significant progress in 48 days. Other users expressed interest in trying these treatments, asked about side effects, and one noted that they've observed good results in black people.

Pyrilutamide, a potential hair loss treatment that has recently been released for sale, and is thought to have similar efficacy to Dutasteride without side effects. It was discussed in terms of its effectiveness compared to Finasteride, its use by females, and whether it can be safely mixed with RU58841.

User took Fin for 3 years, Dut for 7 months, and oral Min for 2 months without side effects. Fin stopped hair loss for 2 years, Dut maintained hair, and oral Min regrew thinning hair.

OP experienced thicker hair and less shedding with Nutrafol Women’s Balance but had flushing due to ingredients, and is considering switching to Viviscal Pro with saw palmetto. A user shared that Viviscal increased shedding for both him and his girlfriend, and suggested stopping Nutrafol if the hair loss is due to Telogen effluvium.

The conversation discusses switching from oral to topical treatments for hair loss, specifically using a mix of retinoic acid, finasteride, and minoxidil, after oral treatments like dutasteride and finasteride were ineffective. The user is concerned about the cost and potential impact of dandruff on the absorption of topical treatments.

The user is using a combination of oral Dutasteride and Minoxidil, and a topical formula with Finasteride, Minoxidil, and Hydrocortisone, along with rosemary oil, coconut oil, ginseng, and a derma roller. They are also using LLLT therapy and are questioning the timing of the laser cap session in relation to the topical application.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.

TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.